Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems

被引:34
|
作者
Li, Ang [1 ,12 ]
La, Jennifer [2 ]
May, Sarah B. [3 ]
Guffey, Danielle [3 ]
da Costa, Wilson L., Jr. [4 ]
Amos, Christopher I. [3 ,4 ]
Bandyo, Raka [5 ]
Milner, Emily M. [6 ]
Kurian, Karen M. [6 ]
Chen, Daniel C. R. [2 ,7 ]
Do, Nhan V. [2 ,7 ]
Granada, Carolina [1 ]
Riaz, Nimrah [1 ]
Brophy, Mary T. [2 ,8 ]
Chitalia, Vipul [2 ,9 ,10 ]
Gaziano, J. Michael [2 ]
Garcia, David A.
Carrier, Marc
Flowers, Christopher R.
Zakai, Neil A. [11 ]
Fillmore, Nathanael R. [2 ,8 ]
机构
[1] Baylor Coll Med, Sect Hematol Oncol, Houston, TX 77030 USA
[2] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA
[3] Baylor Coll Med, Inst Clin & Translat Res, Houston, TX 77030 USA
[4] Baylor Coll Med, Sect Epidemiol & Populat Sci, Houston, TX 77030 USA
[5] Harris Hlth Syst, Houston, TX USA
[6] Baylor Coll Med, Sch Med, Houston, TX 77030 USA
[7] Boston Univ, Sch Med, Sect Gen Internal Med, Boston, MA USA
[8] Boston Univ, Sch Med, Sect Hematol & Med Oncol, Boston, MA USA
[9] Boston Univ, Sch Med, Dept Med, Renal Sect, Boston, MA USA
[10] MIT, Inst Med Engn & Sci, Cambridge, MA USA
[11] Univ Vermont, Larner Coll Med, Dept Pathol & Lab Med, Burlington, VT USA
[12] Baylor Coll Med, One Baylor Plaza,011DF, Houston, TX 77030 USA
关键词
PATIENTS RECEIVING CHEMOTHERAPY; VENOUS THROMBOEMBOLISM; PREDICTION; THROMBOPROPHYLAXIS; SCORE;
D O I
10.1200/JCO.22.01542
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Venous thromboembolism (VTE), especially pulmonary embolism (PE) and lower extremity deep vein thrombosis (LE-DVT), is a serious and potentially preventable complication for patients with cancer undergoing systemic therapy. METHODS Using retrospective data from patients diagnosed with incident cancer from 2011-2020, we derived a parsimonious risk assessment model (RAM) using least absolute shrinkage and selection operator regression from the Harris Health System (HHS, n59,769) and externally validated it using the Veterans Affairs (VA) health care system (n 5 79,517). Bootstrapped c statistics and calibration curves were used to assess external model discrimination and fit. Dichotomized risk strata using integer scores were created and compared against the Khorana score (KS). RESULTS Incident VTE and PE/LE-DVT at 6 months occurred in 590 (6.2%) and 437 (4.6%) patients in HHS and 4,027 (5.1%) and 3,331 (4.2%) patients in the VA health care system. Assessed at the time of systemic therapy initiation, the new RAM included components of the KS with the modified cancer subtype, cancer staging, systemic therapy class, history of VTE, history of paralysis/immobility, recent hospitalization, and Asian/Pacific Islander race. The c statistic was 0.71 in HHS and 0.68 in the VA health care system (compared with 0.65 and 0.60, respectively, for KS). Furthermore, the new RAM appropriately reclassified 28% of patients and increased the proportion of VTEs in the high-risk group from 37% to 68% in the validation data set. CONCLUSION The novel RAM stratified patients with cancer into a high-risk group with 8%-10% cumulative incidence of VTE and 7% PE/LE-DVT at 6 months (v 3% and 2%, respectively, in the low-risk group). The model had improved performance over the original KS and doubled the number of VTE events in the high-risk stratum. We encourage additional external validation from prospective studies.
引用
收藏
页码:2926 / +
页数:14
相关论文
共 21 条
  • [1] Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study
    Syrigos, Konstantinos
    Grapsa, Dimitra
    Sangare, Rabiatou
    Evmorfiadis, Ilias
    Larsen, Annette K.
    Van Dreden, Patrick
    Boura, Paraskevi
    Charpidou, Andriani
    Kotteas, Elias
    Sergentanis, Theodoros N.
    Elalamy, Ismail
    Falanga, Anna
    Gerotziafas, Grigoris T.
    ONCOLOGIST, 2018, 23 (11) : 1372 - 1381
  • [2] Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma
    Li, Ang
    Wu, Qian
    Luo, Suhong
    Warnick, Greg S.
    Zakai, Neil A.
    Libby, Edward N.
    Gage, Brian F.
    Garcia, David A.
    Lyman, Gary H.
    Sanfilippo, Kristen M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (07): : 840 - +
  • [3] Risk assessment for cancer-associated thrombosis: What is the best approach?
    Khorana, Alok A.
    THROMBOSIS RESEARCH, 2012, 129 : S10 - S15
  • [4] Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model
    Sud, Rohit
    Khorana, Alok A.
    THROMBOSIS RESEARCH, 2009, 123 : S18 - S21
  • [5] Cancer-Associated Thrombosis: A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies
    Mosaad, Manar
    Elnaem, Mohamed Hassan
    Cheema, Ejaz
    Ibrahim, Ismail
    Ab Rahman, Jamalludin
    Kori, Ahlam Naila
    Hin, How Soon
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 3881 - 3897
  • [6] In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients
    Poenou, Geraldine
    Toledano, Emmanuel
    Helfer, Helene
    Plaisance, Ludovic
    Happe, Florent
    Versini, Edouard
    Diab, Nevine
    Djennaoui, Sadji
    Mahe, Isabelle
    CANCERS, 2022, 14 (08)
  • [7] Prediction of mortality in acute pulmonary embolism in cancer-associated thrombosis (MAUPE-C): derivation and validation of a multivariable model
    Aramberri, Mario
    Gonzalez-Olmedo, Jesus
    Garcia-Villa, Adrian
    Villanueva, Ane
    Maza, Cristina Castillo
    Garcia-Gutierrez, Susana
    Diaz-Pedroche, Carmen
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (04) : 668 - 676
  • [8] Cancer-Associated Thrombosis: Epidemiology, Pathophysiological Mechanisms, Treatment, and Risk Assessment
    Pavlovic, Dragica
    Niciforovic, Danijela
    Markovic, Marina
    Papic, Dragana
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2023, 17
  • [9] External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis
    Astruc, Nolwenn
    Ianotto, Jean-Christophe
    Metges, Jean-Philippe
    Lacut, Karine
    Delluc, Aurelien
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 36 : E11 - E12
  • [10] External validation of a novel cancer-associated venous thromboembolism risk assessment score in a safety-net hospital
    Dulberger, Karlynn N.
    La, Jennifer
    Li, Ang
    Lotfollahzadeh, Saran
    Jose, Asha
    Do, Nhan, V
    Brophy, Mary T.
    Gaziano, J. Michael
    Ravid, Katya
    Chitalia, Vipul C.
    Fillmore, Nathanael R.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2025, 9 (01)